Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones related protein associated with corticosteroid therapy

Alan Solomon, C. L. McLaughlin, J. D. Capra

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Urine specimens from patients with multiple myeloma and Bence Jones proteinuria frequently contain low molecular weight proteins which correspond either to the amino terminal, variant half (V[L]) or to the carboxyl terminal, constant half (C[L]) of the Bence Jones protein. Analyses of urine specimens from such patients who had received high doses of corticosteroids as part of their treatment regimen revealed that concomitantly with a decrease in Bence Jones protein excretion was the appearance of a low molecular weight protein related to the Bence Jones protein but not identical to the V(L) or to the C(L). Analysis of daily urine specimens obtained from one such patient over an extended time period revealed that a reproducible chain of events occurred during a treatment regimen which included oral administration of 75 mg of prednisone daily for 7 consecutive days. The amount of Bence Jones protein excreted decreased progressively, and by the 5th day was usually less than 10% of the pretreatment value. The urine specimen obtained on the 6th day of treatment was virtually devoid of Bence Jones protein but contained a newly appearing protein whose electrophoretic mobility was distinct from that of the Bence Jones protein or its V(L) or C(L). Cessation of corticosteroid therapy resulted in a prompt disappearance of the new protein and in a progressive increase in the amount of Bence Jones protein excreted. The new protein was isolated from the urine of this patient and was purified for comparative studies with Bence Jones protein and with the V(L) and C(L) prepared by specific enzymatic cleavage of the Bence Jones protein. These studies revealed that the new protein was most related antigenically to the C(L), but could be distinguished immunochemically from the C(L). This new protein, a component found in vivo related to the constant half of the light polypeptide chain, was designated C(L)*, and was structurally 25 amino acid residues longer than the C(L), that is, the amino terminus of the enzymatically prepared C(L) was at position 117 whereas that of the transitory new Bence Jones related protein was at position 92 of the light polypeptide chain. Biosynthetic studies were performed with plasma cells derived from the bone marrow of this patient at a time when the C(L)* and the Bence Jones protein were being excreted; both proteins were identified in extracellular culture fluid by immunochemical techniques. Whether the C(L)* is of synthetic or catabolic origin is presently not known; however, the detection of the C(L)* and the absence of any detectable protein related to the V(L) in the extracellular culture fluid might imply a synthetic origin of the C(L)* and suggest a corticosteroid induced alteration in light chain synthesis.

Original languageEnglish (US)
Pages (from-to)579-586
Number of pages8
JournalJournal of Clinical Investigation
Volume55
Issue number3
DOIs
StatePublished - Jan 1 1975

Fingerprint

Bence Jones Protein
Immunoglobulin Light Chains
Adrenal Cortex Hormones
Proteins
Urine
Therapeutics
Extracellular Fluid
Light
Molecular Weight
Peptides
Prednisone
Plasma Cells
Multiple Myeloma
Proteinuria
Oral Administration

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones related protein associated with corticosteroid therapy. / Solomon, Alan; McLaughlin, C. L.; Capra, J. D.

In: Journal of Clinical Investigation, Vol. 55, No. 3, 01.01.1975, p. 579-586.

Research output: Contribution to journalArticle

@article{602bfcea707246e09611eef96a2e8cf4,
title = "Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones related protein associated with corticosteroid therapy",
abstract = "Urine specimens from patients with multiple myeloma and Bence Jones proteinuria frequently contain low molecular weight proteins which correspond either to the amino terminal, variant half (V[L]) or to the carboxyl terminal, constant half (C[L]) of the Bence Jones protein. Analyses of urine specimens from such patients who had received high doses of corticosteroids as part of their treatment regimen revealed that concomitantly with a decrease in Bence Jones protein excretion was the appearance of a low molecular weight protein related to the Bence Jones protein but not identical to the V(L) or to the C(L). Analysis of daily urine specimens obtained from one such patient over an extended time period revealed that a reproducible chain of events occurred during a treatment regimen which included oral administration of 75 mg of prednisone daily for 7 consecutive days. The amount of Bence Jones protein excreted decreased progressively, and by the 5th day was usually less than 10{\%} of the pretreatment value. The urine specimen obtained on the 6th day of treatment was virtually devoid of Bence Jones protein but contained a newly appearing protein whose electrophoretic mobility was distinct from that of the Bence Jones protein or its V(L) or C(L). Cessation of corticosteroid therapy resulted in a prompt disappearance of the new protein and in a progressive increase in the amount of Bence Jones protein excreted. The new protein was isolated from the urine of this patient and was purified for comparative studies with Bence Jones protein and with the V(L) and C(L) prepared by specific enzymatic cleavage of the Bence Jones protein. These studies revealed that the new protein was most related antigenically to the C(L), but could be distinguished immunochemically from the C(L). This new protein, a component found in vivo related to the constant half of the light polypeptide chain, was designated C(L)*, and was structurally 25 amino acid residues longer than the C(L), that is, the amino terminus of the enzymatically prepared C(L) was at position 117 whereas that of the transitory new Bence Jones related protein was at position 92 of the light polypeptide chain. Biosynthetic studies were performed with plasma cells derived from the bone marrow of this patient at a time when the C(L)* and the Bence Jones protein were being excreted; both proteins were identified in extracellular culture fluid by immunochemical techniques. Whether the C(L)* is of synthetic or catabolic origin is presently not known; however, the detection of the C(L)* and the absence of any detectable protein related to the V(L) in the extracellular culture fluid might imply a synthetic origin of the C(L)* and suggest a corticosteroid induced alteration in light chain synthesis.",
author = "Alan Solomon and McLaughlin, {C. L.} and Capra, {J. D.}",
year = "1975",
month = "1",
day = "1",
doi = "10.1172/JCI107965",
language = "English (US)",
volume = "55",
pages = "579--586",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

TY - JOUR

T1 - Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones related protein associated with corticosteroid therapy

AU - Solomon, Alan

AU - McLaughlin, C. L.

AU - Capra, J. D.

PY - 1975/1/1

Y1 - 1975/1/1

N2 - Urine specimens from patients with multiple myeloma and Bence Jones proteinuria frequently contain low molecular weight proteins which correspond either to the amino terminal, variant half (V[L]) or to the carboxyl terminal, constant half (C[L]) of the Bence Jones protein. Analyses of urine specimens from such patients who had received high doses of corticosteroids as part of their treatment regimen revealed that concomitantly with a decrease in Bence Jones protein excretion was the appearance of a low molecular weight protein related to the Bence Jones protein but not identical to the V(L) or to the C(L). Analysis of daily urine specimens obtained from one such patient over an extended time period revealed that a reproducible chain of events occurred during a treatment regimen which included oral administration of 75 mg of prednisone daily for 7 consecutive days. The amount of Bence Jones protein excreted decreased progressively, and by the 5th day was usually less than 10% of the pretreatment value. The urine specimen obtained on the 6th day of treatment was virtually devoid of Bence Jones protein but contained a newly appearing protein whose electrophoretic mobility was distinct from that of the Bence Jones protein or its V(L) or C(L). Cessation of corticosteroid therapy resulted in a prompt disappearance of the new protein and in a progressive increase in the amount of Bence Jones protein excreted. The new protein was isolated from the urine of this patient and was purified for comparative studies with Bence Jones protein and with the V(L) and C(L) prepared by specific enzymatic cleavage of the Bence Jones protein. These studies revealed that the new protein was most related antigenically to the C(L), but could be distinguished immunochemically from the C(L). This new protein, a component found in vivo related to the constant half of the light polypeptide chain, was designated C(L)*, and was structurally 25 amino acid residues longer than the C(L), that is, the amino terminus of the enzymatically prepared C(L) was at position 117 whereas that of the transitory new Bence Jones related protein was at position 92 of the light polypeptide chain. Biosynthetic studies were performed with plasma cells derived from the bone marrow of this patient at a time when the C(L)* and the Bence Jones protein were being excreted; both proteins were identified in extracellular culture fluid by immunochemical techniques. Whether the C(L)* is of synthetic or catabolic origin is presently not known; however, the detection of the C(L)* and the absence of any detectable protein related to the V(L) in the extracellular culture fluid might imply a synthetic origin of the C(L)* and suggest a corticosteroid induced alteration in light chain synthesis.

AB - Urine specimens from patients with multiple myeloma and Bence Jones proteinuria frequently contain low molecular weight proteins which correspond either to the amino terminal, variant half (V[L]) or to the carboxyl terminal, constant half (C[L]) of the Bence Jones protein. Analyses of urine specimens from such patients who had received high doses of corticosteroids as part of their treatment regimen revealed that concomitantly with a decrease in Bence Jones protein excretion was the appearance of a low molecular weight protein related to the Bence Jones protein but not identical to the V(L) or to the C(L). Analysis of daily urine specimens obtained from one such patient over an extended time period revealed that a reproducible chain of events occurred during a treatment regimen which included oral administration of 75 mg of prednisone daily for 7 consecutive days. The amount of Bence Jones protein excreted decreased progressively, and by the 5th day was usually less than 10% of the pretreatment value. The urine specimen obtained on the 6th day of treatment was virtually devoid of Bence Jones protein but contained a newly appearing protein whose electrophoretic mobility was distinct from that of the Bence Jones protein or its V(L) or C(L). Cessation of corticosteroid therapy resulted in a prompt disappearance of the new protein and in a progressive increase in the amount of Bence Jones protein excreted. The new protein was isolated from the urine of this patient and was purified for comparative studies with Bence Jones protein and with the V(L) and C(L) prepared by specific enzymatic cleavage of the Bence Jones protein. These studies revealed that the new protein was most related antigenically to the C(L), but could be distinguished immunochemically from the C(L). This new protein, a component found in vivo related to the constant half of the light polypeptide chain, was designated C(L)*, and was structurally 25 amino acid residues longer than the C(L), that is, the amino terminus of the enzymatically prepared C(L) was at position 117 whereas that of the transitory new Bence Jones related protein was at position 92 of the light polypeptide chain. Biosynthetic studies were performed with plasma cells derived from the bone marrow of this patient at a time when the C(L)* and the Bence Jones protein were being excreted; both proteins were identified in extracellular culture fluid by immunochemical techniques. Whether the C(L)* is of synthetic or catabolic origin is presently not known; however, the detection of the C(L)* and the absence of any detectable protein related to the V(L) in the extracellular culture fluid might imply a synthetic origin of the C(L)* and suggest a corticosteroid induced alteration in light chain synthesis.

UR - http://www.scopus.com/inward/record.url?scp=0016661068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016661068&partnerID=8YFLogxK

U2 - 10.1172/JCI107965

DO - 10.1172/JCI107965

M3 - Article

C2 - 803979

AN - SCOPUS:0016661068

VL - 55

SP - 579

EP - 586

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -